Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study

View Full Paper
Ask AI
Bookmark
Share

Authors

GWGuoqing WangMerck & Co., Inc., Rahway, NJ, USA (United States)

Discussion

Loading...

Member takes

Implication

Randomized trial compares zilovertamab vedotin plus R-CHP to polatuzumab vedotin plus R-CHP in GCB DLBCL patients, assessing complete response and safety.

Key Points

  • To evaluate the efficacy and safety of zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP in previously untreated GCB DLBCL participants.
  • Randomized, open-label, Phase 2 study design
  • Participants aged ≥18 with histologically confirmed GCB DLBCL
  • Patients receive zilovertamab or polatuzumab vedotin with R-CHP for up to 6 cycles
  • Primary endpoint is complete response rate determined by BICR
  • Safety and patient-reported outcomes are secondary endpoints.
  • Primary endpoint is the complete response rate as per Lugano criteria
  • Study focuses on previously untreated GCB DLBCL patients
  • Safety assessments and patient-reported outcomes are included.

Cite This Study

Guoqing Wang (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deb9https://doi.org/10.1182/blood-2025-5480
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1waveLINE-011: Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in germinal center B-cell–like (GCB) diffuse large B-cell lymphoma (DLBCL).2026
  2. 2Zilovertamab vedotin plus R-CHP versus R-CHOP for first-line treatment of diffuse large B-cell lymphoma: The phase 3 waveline-010 study2025 · 1 citations
  3. 3Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-0072025 · 1 citations
  4. 4Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-0032025 · 1 citations
  5. 5Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization2025